AcelRx Pharmaceuticals, Inc. (ACRX) earnings
Quarterly and annual ACRX reports and results, each read against the price at its own news timestamp. Back to the ACRX overview →
3 measured ACRX earnings events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q ACELRX PHARMACEUTICALS For: Sep 30 | SEC filing · Form 10-Q | +3.73% | +3.11% | |
| AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update | Press release | -2.76% | -8.60% | |
| AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023 | Press release | +0.00% | -7.83% |
Keep exploring
More ACRX: analyst actions → · SEC filings → · ACRX overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| PACIFIC HLTH CRE ORGZ INC (PFHO) | 33 | 0.00% | 29% |
| Remedent, Inc. (REMI) | 33 | 0.00% | 0% |
| Aravive, Inc. (ARAV) | 32 | +4.15% | 67% |
| Nemaura Medical, Inc. (NMRD) | 32 | 0.00% | 39% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.